News

Immatics receives $58 million in financing to develop T-cell receptor based immunotherapies

Details

Immatics today announced the completion of its Series E financing, raising $58 million. 

Immatics initiates first Phase I clinical trial of ACTengine® approach in patients with advanced solid cancers

Details

Immatics today announced that it has initiated enrollment of patients into a Phase I trial of IMA201, its first T-cell Receptor (TCR)-transduced adoptive cell therapy program. 

Wellington featured in BioCentury

Details

RIG-GING AN EXIT: Rigontec takeout gives Wellington quick exit, momentum into new Fund. 

  1. MSD to acquire Rigontec
  2. Themis: Chikungunya vaccine development towards Phase III trials receives £ 3 Mio. boost by Innovate UK
  3. Immatics initiates personalized adoptive cellular therapy in patients with relapsed and/or refractory solid cancers using its pioneering target warehouse
  4. Themis starts Phase II clinical study of Chikungunya vaccine in endemic area
© Wellington Partners, 2019.